Singapore: Japan's Takeda Pharmaceutical has appointed Dr Andrew Plump as corporate officer and chief medical and scientific officer (CMSO), effective from February 1, 2015.

Dr Plump will lead Takeda's global R&D operations and will report directly to Mr Christophe Weber, president and Chief Operating Officer, Takeda.

"I am fully confident that Andy, with his deep experience in drug discovery and development and his past work in areas directly relevant to Takeda, will sustain and enhance our best-in-class R&D enterprise," said Mr Christophe Weber, president and chief operating officer, Takeda. "Andy has a deep passion for leveraging breakthroughs in science to improve patients' lives, which is in line with Takeda's mission and fully reflects our core values of Takeda-ism."